Sinopharm ramps up efforts to fight epidemic - (China Daily via NewsPoints Desk)

  • Sinopharm, also known as China National Pharmaceutical Group, said its R&D efforts for vaccines against COVID-19 have made substantial progress, while treatment supplies for the infection are also to be increased, reported China Daily.

  • Two affiliates of China National Biotech Group (CNBG), Sinopharm's subsidiary for vaccine and biological medicine, are working to develop inactivated vaccines.

  • The Wuhan subsidiary in Hubei province is currently cultivating the virus, while the Beijing subsidiary is building the virus seed stock together with Chinese Center for Disease Control and Prevention.

  • Changchun Institute of Biological Products, CNBG's subsidiary in the capital city of Jilin province, is working at full operation to produce interferon-alpha, a treatment recommended by Chinese health authorities. In early March, the monthly production capacity is expected to reach 1 million vials, the news source said.

  • Shanghai GeneoDx Biotech, an affiliate of CNBG, had provided the virus infection test kits for 1 million people's use by February 10, and is able to produce 4000 packs of test kits daily with expanded capacity, which can be used on 200,000 people.

  • According to the news source, Shanghai GeneoDx is one of the first three companies in China that succeeded in developing the test kits.

To read more NewsPoints articles, click here.

Reference Articles